Ember LifeSciences has entered into a capital and business alliance with Alfresa Corporation.

Alfresa will partner with Ember to improve the quality of pharmaceutical cold chain logistics across Japan, including evaluating the Ember Cube and related technologies for Alfresa's Home Care Delivery service, which delivers specialty pharmaceuticals directly from medical institutions to patients' homes.

As part of the new alliance, Alfresa will provide financial support for Ember's business expansion through an investment in Series A preferred stock issued by Ember, strengthening collaboration between the 2 companies. Other investors in the Ember Series A include Amgen, Cardinal Health, Carrier and Sea Court Capital. Through the agreement, Alfresa obtains the exclusive sales rights in Japan's healthcare sector for solutions provided by Ember.

Clay Alexander, Founder and CEO, Ember, said, "We are deeply honored to partner with Alfresa, a company whose legacy of excellence and market leadership we hold in the highest regard. As our Ember Cube 2 continues to gain international acclaim for its revolutionary design, this strategic investment and distribution alliance marks a pivotal milestone. Together, Alfresa and Ember share a profound commitment to bringing unprecedented precision, confidence and reliability to pharmaceutical cold chain logistics for patients throughout Japan."

Ember provides pharmaceutical manufacturers, distributors and healthcare providers with cold chain solutions that combine temperature control with real-time shipment visibility. The Ember Cube maintains a temperature range of 2°C to 8°C for over 72 hours while continuously monitoring shipment conditions and location. Its reusable design also helps reduce packaging waste compared with traditional single-use shipping materials.

Yusuke Fukujin, Representative Director and President, Alfresa, said, "The rapid growth of biopharmaceuticals and vaccines—with the number of temperature?sensitive products increasing each year—demands absolute precision in cold chain logistics. Alfresa has been strengthening its capabilities in this space through continuous investment in next generation technologies. I am very excited about this partnership with Ember, which reinforces our commitment to advance cold chain pharmaceutical logistics in the Japanese market."